ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada
News Dec 30, 2013
ThromboGenics NV has announced that JETREA® has received a positive Common Drug Review (CDR) in Canada. ThromboGenics signed a strategic partnership in 2012 with Alcon, a division of Novartis, for the commercialization of JETREA® outside of the United States.
In August 2013, Health Canada approved JETREA® (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). In November, JETREA® was made commercially available to Canadians who suffer from this sight-threatening condition.
The Common Drug Review, which is carried out by the Canadian Agency for Drugs and Technologies in Health (CADTH), is a pan-Canadian process for conducting objective, rigorous reviews of the clinical, cost-effectiveness, and patient evidence for drugs.
JETREA® is already covered by most of the major private payers in Canada.
ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.
Dr Patrik De Haes, CEO of ThromboGenics said: “I am pleased that JETREA® has received a positive Common Drug Review in Canada. To-date only 30% of all first-in-class products has received a positive CDR listing recommendation. This follows and confirms positive outcomes with the reimbursement agencies in the UK and Germany. I believe today’s CDR review and recognition of the clinical and economic value of this novel treatment for symptomatic VMA augurs well for the future success of JETREA®.”
In Europe, JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
Alcon has launched JETREA® in the UK, Germany, Finland, Denmark, Norway, Sweden and Canada.
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE